Hormone refractory prostate cancer: Management and advances.

Published

Journal Article (Review)

Effective therapeutic options have not existed for prostate cancer progressing after androgen deprivation therapy until very recently. Secondary hormonal manipulations offer marginal benefits. Docetaxel based chemotherapy has been demonstrated to extend survival and change the natural history of the disease in two large randomized trials. These studies have provided the impetus to combine docetaxel with novel biologic agents to further consolidate the gains in long-term outcome. With the arrival of exciting agents including vaccines, monoclonal antibodies, bone-targeted drugs, antisense oligonucleotides, anti-angiogenic drugs and small molecule receptor tyrosine kinase inhibitors, the future treatment of prostate cancer appears promising.

Full Text

Duke Authors

Cited Authors

  • Sonpavde, G; Hutson, TE; Berry, WR

Published Date

  • April 2006

Published In

Volume / Issue

  • 32 / 2

Start / End Page

  • 90 - 100

PubMed ID

  • 16458434

Pubmed Central ID

  • 16458434

International Standard Serial Number (ISSN)

  • 0305-7372

Digital Object Identifier (DOI)

  • 10.1016/j.ctrv.2005.12.005

Language

  • eng

Conference Location

  • Netherlands